Transaction DateRecipientSharesTypePriceValue
4th January 2021Philip H Coelho13,513Grant/award etc.$1.48$19,999.24
22nd December 2020Patrick J Mcenany7,507Payment by withholding$0.00
22nd December 2020Charles B O'Keeffe1,333Exercise of derivative$0.00
22nd December 2020Patrick J Mcenany30,833Exercise of derivative$0.00
22nd December 2020Steve Miller20,000Exercise of derivative$0.00
22nd December 2020Philip H Coelho1,333Exercise of derivative$0.00
22nd December 2020Gary Ingenito3,668Open or private sale$3.45$12,643.60
22nd December 2020Gary Ingenito14,666Exercise of derivative$0.00
22nd December 2020Richard J Daly1,333Exercise of derivative$0.00
22nd December 2020David S Tierney1,333Exercise of derivative$0.00
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Catalyst Pharmaceuticals is a biopharmaceutical company. The company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL. It is developing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.


Ticker: CPRX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1369568
Employees: 76
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $115 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $131 M (17%)
Property, Plant and Equipment, Net: $168 Th (-20%)
Assets: $131 M (16%)
Accounts Payable, Current: $6 M (40%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $20 M (-16%)
Liabilities: $20 M (-18%)
Common Stock, Value, Issued: $103 Th (0%)
Common Stock, Shares, Issued: $103 M (0%)
Retained Earnings (Accumulated Deficit): $108 M (-15%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 Th (-87%)
Stockholders' Equity (Parent): $111 M (0%)
Liabilities and Equity: $131 M (16%)
Revenue: $30 M (-49%)
Cost of Revenue: $4 M (-50%)
Research and Development: $4 M (-49%)
Operating Income/Loss: $10 M (-50%)
Provision for income taxes: $613 Th (-49%)
EPS (basic): $0.09 (-55%)
EPS (diluted): $0.09 (-52%)